Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.

Alig L, Alsenz J, Andjelkovic M, Bendels S, Bénardeau A, Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S, Kube D, Lübbers T, Mayweg AV, Narquizian R, Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, Röver S, Schneider G, Taylor S, Waldmeier P.

J Med Chem. 2008 Apr 10;51(7):2115-27. doi: 10.1021/jm701487t. Epub 2008 Mar 13.

PMID:
18335976
2.

Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.

Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W.

Int J Obes (Lond). 2008 May;32(5):863-70. doi: 10.1038/ijo.2008.3. Epub 2008 Feb 5.

PMID:
18253160
3.

Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA.

Woltering TJ, Adam G, Huguenin P, Wichmann J, Kolczewski S, Gatti S, Bourson A, Kew JN, Richards G, Kemp JA, Mutel V, Knoflach F.

ChemMedChem. 2008 Feb;3(2):323-35.

PMID:
18058780
4.

Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.

Röver S, Adams DR, Bénardeau A, Bentley JM, Bickerdike MJ, Bourson A, Cliffe IA, Coassolo P, Davidson JE, Dourish CT, Hebeisen P, Kennett GA, Knight AR, Malcolm CS, Mattei P, Misra A, Mizrahi J, Muller M, Porter RH, Richter H, Taylor S, Vickers SP.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3604-8.

PMID:
15975787
5.

1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists.

Alanine A, Bourson A, Büttelmann B, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3155-9.

PMID:
12951084
6.

4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.

Büttelmann B, Alanine A, Bourson A, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R.

Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.

PMID:
12729659
7.

2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.

Büttelmann B, Alanine A, Bourson A, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R.

Bioorg Med Chem Lett. 2003 Mar 10;13(5):829-32.

PMID:
12617901
8.

New anti-MRSA and anti-VRE carbapenems; synthesis and structure-activity relationships of 1beta-methyl-2-(thiazol-2-ylthio)carbapenems.

Sunagawa M, Itoh M, Kubota K, Sasaki A, Ueda Y, Angehrn P, Bourson A, Goetschi E, Hebeisen P, Then RL.

J Antibiot (Tokyo). 2002 Aug;55(8):722-57.

9.

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.

Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA.

J Pharmacol Exp Ther. 2002 Sep;302(3):940-8.

PMID:
12183650
10.

4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.

Pinard E, Alanine A, Bourson A, Büttelmann B, Heitz M, Mutela Ramanjit Gill V, Trube G, Wyler R.

Bioorg Med Chem Lett. 2002 Sep 16;12(18):2615-9.

PMID:
12182873
11.

Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.

Pinard E, Alanine A, Bourson A, Büttelmann B, Gill R, Heitz M, Jaeschke G, Mutel V, Trube G, Wyler R.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2173-6.

PMID:
11514163
12.

Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.

Bentley JC, Bourson A, Boess FG, Fone KC, Marsden CA, Petit N, Sleight AJ.

Br J Pharmacol. 1999 Apr;126(7):1537-42.

13.

Residues in transmembrane regions III and VI contribute to the 5-ht6 receptor ligand binding site.

Boess FG, Monsma FJ Jr, Bourson A, Zwingelstein C, Sleight AJ.

Ann N Y Acad Sci. 1998 Dec 15;861:242-3. No abstract available.

PMID:
9928266
14.

The putative 5-ht6 receptor: localization and function.

Sleight AJ, Boess FG, Bös M, Bourson A.

Ann N Y Acad Sci. 1998 Dec 15;861:91-6. Review.

PMID:
9928244
15.

Involvement of 5-HT6 receptors in nigro-striatal function in rodents.

Bourson A, Boess FG, Bös M, Sleight AJ.

Br J Pharmacol. 1998 Dec;125(7):1562-6.

16.

The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.

Boess FG, Riemer C, Bös M, Bentley J, Bourson A, Sleight AJ.

Mol Pharmacol. 1998 Sep;54(3):577-83.

PMID:
9730917
17.

Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors.

Sleight AJ, Boess FG, Bös M, Levet-Trafit B, Riemer C, Bourson A.

Br J Pharmacol. 1998 Jun;124(3):556-62.

18.

Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice.

Bourson A, Kapps V, Zwingelstein C, Rudler A, Boess FG, Sleight AJ.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):820-6.

PMID:
9453469
19.

Orphan receptors and their natural ligands.

Civelli O, Nothacker HP, Bourson A, Ardati A, Monsma F, Reinscheid R.

J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):545-50. Review. No abstract available.

PMID:
9029514
20.

Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine.

Bourson A, Wanner D, Wyler R, Petit N, Zwingelstein C, Rudler A, Sleight AJ.

Pharmacol Biochem Behav. 1996 Jan;53(1):107-14.

PMID:
8848438
21.

Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides.

Sleight AJ, Monsma FJ Jr, Borroni E, Austin RH, Bourson A.

Behav Brain Res. 1996;73(1-2):245-8.

PMID:
8788511
22.

Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O.

Science. 1995 Nov 3;270(5237):792-4.

PMID:
7481766
23.

Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.

Bourson A, Borroni E, Austin RH, Monsma FJ Jr, Sleight AJ.

J Pharmacol Exp Ther. 1995 Jul;274(1):173-80.

PMID:
7616396
24.

Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment.

Sleight AJ, Carolo C, Petit N, Zwingelstein C, Bourson A.

Mol Pharmacol. 1995 Jan;47(1):99-103.

PMID:
7838138
25.

An investigation into the discriminative stimulus and reinforcing properties of the CCKB-receptor antagonist, L-365,260 in rats.

Jackson A, Tattersall D, Bentley G, Rycroft W, Bourson A, Hargreaves R, Tricklebank M, Iversen S.

Neuropeptides. 1994 May;26(5):343-53.

PMID:
8065550
26.

Curative effects of the atypical antidepressant mianserin in the chronic mild stress-induced anhedonia model of depression.

Moreau JL, Bourson A, Jenck F, Martin JR, Mortas P.

J Psychiatry Neurosci. 1994 Jan;19(1):51-6.

27.
28.
29.

The effects of dihydropyridine compounds in behavioural tests of dopaminergic activity.

Bourson A, Gower AJ, Mir AK, Moser PC.

Br J Pharmacol. 1989 Dec;98(4):1312-8.

30.

Central and peripheral effects of the dihydropyridine calcium channel activator BAY K 8644 in the rat.

Bourson A, Moser PC, Gower AJ, Mir AK.

Eur J Pharmacol. 1989 Feb 7;160(3):339-47.

PMID:
2469593

Supplemental Content

Loading ...
Support Center